#KO
### ğŸ’Š ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - íš¨ëŠ¥ ë° íš¨ê³¼
* ì´ ì•½ì€ ê³„ì ˆì„± ë° ë‹¤ë…„ì„± ì•Œë ˆë¥´ê¸°ì„± ë¹„ì—¼, ì•Œë ˆë¥´ê¸°ì„± ê²°ë§‰ì—¼, ë§Œì„± íŠ¹ë°œì„± ë‘ë“œëŸ¬ê¸°, í”¼ë¶€ê°€ë ¤ì›€ì¦ê³¼Â í•˜ì´ë“œë¡œì½”í‹°ì† ì™¸ìš©ì œì™€ ë³‘ìš©ì— ì˜í•œ ìŠµì§„, í”¼ë¶€ì—¼ì— ì‚¬ìš©í•©ë‹ˆë‹¤.

### ğŸ•’ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ìš©ë²• ë° ìš©ëŸ‰
* ì„±ì¸ ë° 6ì„¸ ì´ìƒì˜ ì†Œì•„ëŠ” 1ì¼ 1íšŒ 1ì •(10 mg)ì„ ì·¨ì¹¨ ì „ì— ë³µìš©í•˜ê³ , ì´ìƒë°˜ì‘ì— ë¯¼ê°í•œ í™˜ìì˜ ê²½ìš°ëŠ”Â 1/2ì •(5 mg)ì”©ì„ ì•„ì¹¨, ì €ë…ì— ë¶„í•  ë³µìš©í•©ë‹ˆë‹¤.

ì—°ë ¹, ì¦ìƒì— ë”°ë¼ ì ì ˆíˆ ì¦ê°í•©ë‹ˆë‹¤.

ì‹ ì¥ì•  í™˜ìì˜ íˆ¬ì—¬ ê°„ê²©ì€ í™˜ìì˜ ì‹ ê¸°ëŠ¥ì— ë”°ë¼ ì¡°ì ˆë˜ì–´ì•¼ í•˜ê³ , ì‹ ì¥ì• ë¥¼ ê°€ì§„ ì†Œì•„ í™˜ìëŠ” í™˜ìì˜ ì‹  ì²­ì†Œìœ¨ê³¼ ì²´ì¤‘ì„ ê³ ë ¤í•˜ì—¬ ê°œë³„ì ìœ¼ë¡œ ìš©ëŸ‰ì„ ì¡°ì ˆí•´ì•¼ í•˜ë¯€ë¡œ ìì„¸í•œ ì‚¬í•­ì€ í—ˆê°€ì‚¬í•­ì„ ì°¸ê³ í•˜ì‹­ì‹œì˜¤.

### âš ï¸ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ì£¼ì˜ì‚¬í•­
* ì •ë³´ ì—†ìŒ
* ì´ ì•½ ë°Â íˆë“œë¡ì‹œì§„ ë˜ëŠ” í”¼í˜ë¼ì§„ ìœ ë„ì²´ì— ê³¼ë¯¼ì¦ í™˜ì, ì‹ ë¶€ì „ í™˜ì(í¬ë ˆì•„í‹°ë‹Œ ì²­ì†Œìœ¨ 

ì´ ì•½ì„ ë³µìš©í•˜ê¸° ì „ì— ì„ë¶€, ìˆ˜ìœ ë¶€, ì‹ ì¥ì• (ì‹ ì¥ì¥ì• ), ê°„ì¥ì•  í™˜ì, ë…¸ì¸,Â ê°„ì§ˆ ë° ë°œì‘ ìœ„í—˜ì„±ì´ ìˆëŠ” í™˜ì,Â ì†Œë³€ê³ ì„ì˜ ì„ í–‰ìš”ì¸(ì²™ìˆ˜ ë³‘ë³€, ì „ë¦½ì„  ë¹„ëŒ€ì¦)ì´ ìˆëŠ” í™˜ìëŠ” ì˜ì‚¬ ë˜ëŠ” ì•½ì‚¬ì™€ ìƒì˜í•˜ì‹­ì‹œì˜¤.

#EN
### ğŸ’Š ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Efficacy and Effects
*   This medicine is used for seasonal and perennial allergic rhinitis, allergic conjunctivitis, chronic idiopathic urticaria, pruritus, and in combination with topical hydrocortisone for eczema and dermatitis.

### ğŸ•’ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Dosage and Administration
*   Adults and children 6 years of age and older should take 1 tablet (10 mg) once daily before bedtime. For patients sensitive to adverse reactions, take 1/2 tablet (5 mg) in divided doses, morning and evening.
*   The dosage may be appropriately increased or decreased according to age and symptoms.
*   The dosing interval for patients with renal impairment should be adjusted according to the patient's renal function. For pediatric patients with renal impairment, the dosage should be individualized considering the patient's renal clearance and body weight. Please refer to the full prescribing information for detailed instructions.

### âš ï¸ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Precautions
*   This medicine should not be taken by patients with hypersensitivity to this drug, hydroxyzine, or piperazine derivatives, and patients with renal failure (creatinine clearance <10 mL/min).
*   Before taking this medicine, pregnant women, nursing mothers, patients with renal impairment, hepatic impairment, the elderly, patients with epilepsy and a risk of seizures, and patients with predisposing factors for urinary retention (e.g., spinal cord lesions, prostatic hyperplasia) should consult a doctor or pharmacist.

---

#CN
### ğŸ’Š ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - åŠŸæ•ˆä¸ä½œç”¨
*   æœ¬å“ç”¨äºå­£èŠ‚æ€§åŠå¸¸å¹´æ€§è¿‡æ•æ€§é¼»ç‚ã€è¿‡æ•æ€§ç»“è†œç‚ã€æ…¢æ€§ç‰¹å‘æ€§è¨éº»ç–¹ã€çš®è‚¤ç˜™ç—’ç—‡ï¼Œå¹¶ä¸å¤–ç”¨æ°¢åŒ–å¯çš„æ¾è”åˆç”¨äºæ¹¿ç–¹å’Œçš®ç‚ã€‚

### ğŸ•’ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ç”¨æ³•ç”¨é‡
*   æˆäººåŠ6å²ä»¥ä¸Šå„¿ç«¥æ¯æ—¥ä¸€æ¬¡ï¼Œç¡å‰æœç”¨1ç‰‡ï¼ˆ10æ¯«å…‹ï¼‰ã€‚å¯¹äºå¯¹ä¸è‰¯ååº”æ•æ„Ÿçš„æ‚£è€…ï¼Œå¯å°†1/2ç‰‡ï¼ˆ5æ¯«å…‹ï¼‰åˆ†æ—©æ™šä¸¤æ¬¡æœç”¨ã€‚
*   æ ¹æ®å¹´é¾„å’Œç—‡çŠ¶ï¼Œå¯é€‚å½“å¢å‡å‰‚é‡ã€‚
*   è‚¾åŠŸèƒ½ä¸å…¨æ‚£è€…çš„ç»™è¯é—´éš”åº”æ ¹æ®æ‚£è€…çš„è‚¾åŠŸèƒ½è¿›è¡Œè°ƒæ•´ã€‚å¯¹äºè‚¾åŠŸèƒ½ä¸å…¨çš„å„¿ç«¥æ‚£è€…ï¼Œåº”æ ¹æ®æ‚£è€…çš„è‚¾æ¸…é™¤ç‡å’Œä½“é‡ä¸ªä½“åŒ–è°ƒæ•´å‰‚é‡ï¼Œè¯¦æƒ…è¯·å‚è€ƒè¯å“è¯´æ˜ä¹¦ã€‚

### âš ï¸ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - æ³¨æ„äº‹é¡¹
*   å¯¹æœ¬å“ã€ç¾Ÿå—ªæˆ–å“Œå—ªè¡ç”Ÿç‰©è¿‡æ•çš„æ‚£è€…ï¼Œä»¥åŠè‚¾åŠŸèƒ½è¡°ç«­æ‚£è€…ï¼ˆè‚Œé…æ¸…é™¤ç‡ï¼œ10 mL/minï¼‰ç¦ç”¨æœ¬å“ã€‚
*   æœç”¨æœ¬å“å‰ï¼Œå­•å¦‡ã€å“ºä¹³æœŸå¦‡å¥³ã€è‚¾åŠŸèƒ½ä¸å…¨æ‚£è€…ã€è‚åŠŸèƒ½ä¸å…¨æ‚£è€…ã€è€å¹´äººã€æœ‰ç™«ç—«åŠæƒŠå¥é£é™©çš„æ‚£è€…ï¼Œä»¥åŠæœ‰å°¿æ½´ç•™è¯±å› ï¼ˆå¦‚è„Šé«“ç—…å˜ã€å‰åˆ—è…ºè‚¥å¤§ï¼‰çš„æ‚£è€…ï¼Œè¯·å’¨è¯¢åŒ»ç”Ÿæˆ–è¯å¸ˆã€‚

---

#JP
### ğŸ’Š ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - åŠ¹èƒ½ãƒ»åŠ¹æœ
*   æœ¬å‰¤ã¯ã€å­£ç¯€æ€§åŠã³é€šå¹´æ€§ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æ€§é¼»ç‚ã€ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æ€§çµè†œç‚ã€æ…¢æ€§ç‰¹ç™ºæ€§è•éº»ç–¹ã€çš®è†šãã†ç—’ç—‡ã€ä¸¦ã³ã«ãƒ’ãƒ‰ãƒ­ã‚³ãƒ«ãƒã‚¾ãƒ³å¤–ç”¨å‰¤ã¨ã®ä½µç”¨ã«ã‚ˆã‚‹æ¹¿ç–¹ã€çš®è†šç‚ã«ç”¨ã„ã¾ã™ã€‚

### ğŸ•’ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ç”¨æ³•ãƒ»ç”¨é‡
*   æˆäººåŠã³6æ­³ä»¥ä¸Šã®å°å…ã¯ã€1æ—¥1å›1éŒ ï¼ˆ10 mgï¼‰ã‚’å°±å¯å‰ã«æœç”¨ã—ã€å‰¯ä½œç”¨ã«æ•æ„Ÿãªæ‚£è€…ã®å ´åˆã¯ã€1/2éŒ ï¼ˆ5 mgï¼‰ãšã¤ã‚’æœã€å¤•ã«åˆ†å‰²ã—ã¦æœç”¨ã—ã¾ã™ã€‚
*   å¹´é½¢ã€ç—‡çŠ¶ã«ã‚ˆã‚Šé©å®œå¢—æ¸›ã—ã¾ã™ã€‚
*   è…æ©Ÿèƒ½éšœå®³æ‚£è€…ã¸ã®æŠ•ä¸é–“éš”ã¯ã€æ‚£è€…ã®è…æ©Ÿèƒ½ã«å¿œã˜ã¦èª¿æ•´ã•ã‚Œã‚‹ã¹ãã§ã‚ã‚Šã€è…æ©Ÿèƒ½éšœå®³ã‚’æœ‰ã™ã‚‹å°å…æ‚£è€…ã¯ã€æ‚£è€…ã®è…ã‚¯ãƒªã‚¢ãƒ©ãƒ³ã‚¹ã¨ä½“é‡ã‚’è€ƒæ…®ã—ã¦å€‹åˆ¥ã«ç”¨é‡ã‚’èª¿æ•´ã™ã‚‹å¿…è¦ãŒã‚ã‚‹ãŸã‚ã€è©³ç´°ã«ã¤ã„ã¦ã¯æ·»ä»˜æ–‡æ›¸ã‚’ã”å‚ç…§ãã ã•ã„ã€‚

### âš ï¸ ì„ë¡œí…Œì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - æ³¨æ„äº‹é …
*   æœ¬å‰¤åŠã³ãƒ’ãƒ‰ãƒ­ã‚­ã‚·ã‚¸ãƒ³ã¾ãŸã¯ãƒ”ãƒšãƒ©ã‚¸ãƒ³èª˜å°ä½“ã«éæ•ç—‡ã®ã‚ã‚‹æ‚£è€…ã€è…ä¸å…¨æ‚£è€…ï¼ˆã‚¯ãƒ¬ã‚¢ãƒãƒ‹ãƒ³ã‚¯ãƒªã‚¢ãƒ©ãƒ³ã‚¹ <10 mL/minï¼‰ã¯ã€æœ¬å‰¤ã‚’æœç”¨ã—ãªã„ã§ãã ã•ã„ã€‚
*   æœ¬å‰¤ã‚’æœç”¨ã™ã‚‹å‰ã«ã€å¦Šå©¦ã€æˆä¹³å©¦ã€è…æ©Ÿèƒ½éšœå®³æ‚£è€…ã€è‚æ©Ÿèƒ½éšœå®³æ‚£è€…ã€é«˜é½¢è€…ã€ã¦ã‚“ã‹ã‚“åŠã³ç™ºä½œã®å±é™ºæ€§ãŒã‚ã‚‹æ‚£è€…ã€å°¿é–‰ã®å…ˆè¡Œè¦å› ï¼ˆè„Šé«„ç—…å¤‰ã€å‰ç«‹è…ºè‚¥å¤§ç—‡ãªã©ï¼‰ãŒã‚ã‚‹æ‚£è€…ã¯ã€åŒ»å¸«ã¾ãŸã¯è–¬å‰¤å¸«ã«ã”ç›¸è«‡ãã ã•ã„ã€‚